By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Despite beating earnings and raising guidance, TMO's stock dropped due to concerns about near-term visibility and potential slowdown in organic growth. The 19x forward P/E multiple may not be cheap given the company's cyclical nature and potential headwinds in biotech funding post-IPO boom.
Risk: Slowdown in organic growth and potential compression of margins due to reduced lab utilization rates and a high debt load.
Opportunity: Potential rebound in IPOs and increased demand for lab equipment and services driven by AI-related spending.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the stocks Jim Cramer shared his thoughts on as he discussed Big Tech’s AI spending. A caller asked whether the stock is a buy, sell, or hold. In response, Cramer said:
I like it here. I see so many IPOs every morning that Carl mentions, and they’re all going to need TMO’s machines. I think you can buy it at this level. I know at 19 times earnings, I’m surprised it is that cheap.
Photo by jason briscoe on Unsplash
Thermo Fisher Scientific Inc. (NYSE:TMO) provides instruments, reagents, consumables, software, and lab services that support scientific research, diagnostics, and drug and vaccine development. Cramer mentioned the stock during the April 23 episode, as he said:
Alright, what just happened to the stock of Thermo Fisher Scientific, the arms dealer to the life sciences industry that I’ve liked for so long? This morning, Thermo Fisher reported what looks like a very solid set of numbers, a modest revenue beat paired with a healthy 19-cent earnings beat off a $5.25 basis. Management also raised their full-year forecast substantially, but their guidance for the current quarter came in light. In response, the stock got obliterated today, plunging $47.28 or 9.2% to the point where the stock’s now down nearly 20%… I think that the market has this wrong… This is a great American company.
While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Thermo Fisher's current valuation is predicated on a recovery in bioprocessing demand that is being structurally delayed by inventory overhang and macroeconomic headwinds in the APAC region."
Cramer’s focus on TMO as an 'arms dealer' for IPOs is a narrative-driven simplification that ignores the current reality of the life sciences sector. While a 19x forward P/E might look attractive historically, it fails to account for the massive post-COVID destocking cycle and the persistent weakness in China, which remains a significant revenue drag. TMO’s guidance miss for the quarter suggests that the recovery in bioprocessing is slower than the market hoped. While the long-term thesis of lab consolidation remains intact, investors are currently paying for a growth profile that the company isn't delivering in the immediate term. I see this as a 'wait and see' situation until organic growth stabilizes.
The bull case rests on the assumption that TMO’s massive scale and M&A integration will allow it to capture outsized market share as smaller, cash-strapped biotech firms consolidate and rely increasingly on outsourced, turnkey lab solutions.
"TMO's 19x forward P/E with raised FY guidance embeds a rare entry into a life sciences oligopoly poised for biopharma capex rebound."
TMO's 9.2% plunge to ~$47 loss after a revenue/EPS beat and substantial FY guidance raise reflects market obsession with light Q2 outlook (forward P/E now ~19x per Cramer), but ignores resilient pharma services (PPD segment) and looming IPO rebound fueling instrument demand. Life sciences 'arms dealer' thesis holds as biopharma capex normalizes post-COVID, with 19-cent EPS beat on $5.25 base signaling margin expansion potential to 25%+ EBITDA. At this valuation versus historical 25-30x troughs, it's a multi-year compounder if China exposure (10-15% revs) doesn't bite amid tariffs—watch Q2 for confirmation.
Light Q2 guide signals persistent weakness in bioproduction and gene therapy demand amid biotech funding drought, risking FY guide cuts and P/E compression to 15x if EPS growth stalls below 10%. Cramer's IPO tailwind bet overlooks historically lumpy capex cycles that could delay recovery.
"TMO's valuation is only 'cheap' if you believe the Q2 guidance miss is transitory noise rather than a signal of slowing biotech spending cycles."
TMO's 9.2% single-day drop despite beating earnings and raising full-year guidance is a classic 'sell the news' event, but Cramer's 19x forward P/E observation deserves scrutiny. Life sciences tools are genuinely structural beneficiaries of biotech/pharma R&D cycles and AI-driven drug discovery. However, the article conflates two separate issues: (1) whether TMO is cheap on valuation, and (2) whether the market's repricing reflects legitimate concerns about Q2 guidance being 'light.' The real question isn't whether TMO is a 'great American company'—it is—but whether 19x is actually cheap for a mature, cyclical business facing potential biotech funding headwinds post-IPO boom.
If Q2 guidance disappointed enough to trigger a 20% correction despite a beat, the market may be pricing in a deceleration cycle that Cramer is dismissing as temporary. Life sciences funding is procyclical; if venture capital tightens, TMO's consumables and instruments revenue could face meaningful headwinds for 12+ months, making 19x forward earnings look expensive, not cheap.
"Near-term upside for TMO hinges on a durable growth trajectory that can sustain a 19x multiple amid biotech capex volatility; otherwise, multiple compression is a real risk."
The article portrays Thermo Fisher (TMO) as a buy at around 19x earnings due to lab equipment demand from a wave of IPOs and AI-related spending. The strongest counter is the stock’s sharp single-session drop after a solid beat and raised full-year guidance, implying investors fear near-term visibility or upper-cycle capex risk. TMO remains tied to biotech funding cycles, clinical-trial activity, and FX/margin dynamics; AI spend by large tech firms may not translate into immediate instrument orders. If Q2 guidance proves conservative or organic growth slows, the 19x forward multiple looks ripe for multiple contraction, even for a high-quality name.
The selloff could be overdone; if the full-year guidance proves sustainable and onshoring-related demand re-accelerates later in the year, TMO could still re-rate and justify the multiple.
"The reliance on a speculative IPO rebound ignores the structural pivot of R&D budgets away from hardware toward software, making TMO's current valuation vulnerable to further P/E compression."
Grok, your reliance on a 'looming IPO rebound' to justify TMO’s valuation is speculative at best. Even with a theoretical IPO uptick, instrument sales carry long lead times and are sensitive to interest rate environments that remain restrictive. You are underestimating the structural shift in biopharma R&D budgets toward AI-driven software rather than traditional hardware. If TMO cannot prove its consumables segment offset the hardware slump, that 19x multiple is a value trap, not a discount.
"TMO's consumables dominance buffers near-term risks, but debt servicing amid slow growth threatens FCF flexibility."
Gemini, your AI software shift overlooks TMO's >70% recurring consumables revenue (instruments/services pull-through), insulating from hardware lumpiness—AI actually accelerates lab throughput, driving more usage. Unmentioned risk: TMO's $25B+ debt load (from PPD/Olink buys) at 4%+ rates eats 10% FCF if growth slows, capping buybacks and forcing dilution if capex stays elevated.
"Recurring revenue doesn't protect against demand destruction if the entire biotech funding cycle contracts."
Grok's 70% consumables argument is sound, but masks a timing problem. Yes, recurring revenue insulates from hardware cycles—but Q2 guidance 'light' suggests consumables *themselves* are weakening, not just instruments. If biotech funding drought reduces lab utilization rates across the board, that 70% recurring base compresses margins faster than Grok's 25%+ EBITDA thesis assumes. The debt load Grok flagged becomes a real constraint if growth decelerates below 8-10%.
"Even with 70% consumables, near-term demand weakness and a large debt burden can erode free cash flow and margins, making the 19x forward multiple look riskier than Grok implies."
Grok's line that >70% recurring consumables insulates TMO from hardware cycles overlooks near-term utilization risk. If Q2 guidance is light and biotech funding slows, consumables growth may slow with it, pressuring margins more than the book suggests. Add a $25B debt load at 4%+ rates eroding FCF and buybacks, potentially triggering dilution or slower deleveraging. In that case, 19x forward looks riskier, not a multi-year slam dunk.
Despite beating earnings and raising guidance, TMO's stock dropped due to concerns about near-term visibility and potential slowdown in organic growth. The 19x forward P/E multiple may not be cheap given the company's cyclical nature and potential headwinds in biotech funding post-IPO boom.
Potential rebound in IPOs and increased demand for lab equipment and services driven by AI-related spending.
Slowdown in organic growth and potential compression of margins due to reduced lab utilization rates and a high debt load.